Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
Exact Sciences (EXAS) PT Raised to $95 at Canaccord Genuity
-
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
-
Canaccord Genuity Reiterates Buy Rating on Exact Sciences (EXAS)
-
Exact Sciences (EXAS) PT Lowered to $85 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $115 at Canaccord Genuity
-
Natera's (NTRA) Signatera Highlighted at Liquid Biopsy Online - Canaccord Genuity
-
Exact Sciences to participate in August investor conference
-
Exact Sciences to participate in August investor conference
-
Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal
-
Exact Sciences (EXAS) PT Raised to $125 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $118 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $87 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $65 at Canaccord Genuity
-
Exact Sciences to participate in Canaccord Genuity Growth Conference
-
Exact Sciences (EXAS) PT Raised to Street High $75 at Canaccord, 'Strong execution in a robust bull market'
-
Exact Sciences (EXAS) PT Raised to $70 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $68 at Canaccord Genuity
-
Exact Sciences (EXAS) PT Raised to $60 at Canaccord Genuity
-
Buy Exact Sciences (EXAS) on Weakness - Canaccord Genuity
-
Exact Sciences (EXAS) PT Lowered to $55 at Canaccord Genuity
-
Exact Sciences (EXAS) Selloff 'Overblown' Says Canaccord, 'We Would Aggressively Buy'
-
Exact Sciences (EXAS) PT Raised to $60 at Canaccord Genuity
-
Exact Sciences to participate in Canaccord Genuity Growth Conference
-
Exact Sciences (EXAS) PT Raised to $45 at Canaccord Genuity Following 2Q
-
Exact Sciences (EXAS): Raising PT Ahead of Earnings - Canaccord
-
Exact Sciences (EXAS) PT Lowered to $38 at Canaccord Genuity After Selling 7M Shares
-
Pre-Open Stock Movers 06/07: (DRWI) (CVNA) (SVRA) Higher; (DLTH) (ALOG) (AMBA) Lower (more...)
-
Pre-Open Stock Movers 05/31: (DAC) (JILL) (ETRM) Higher; (GEMP) (AKTX) (KORS) Lower (more...)
-
Exact Sciences (EXAS) PT Raised to $40 at Canaccord Genuity; 'UNH Adds Cologuard to Commercial Coverage'
-
Canaccord Genuity Disagrees with Citron Report on Exact Sciences (EXAS)
-
Exact Sciences to participate in November investor conferences
-
Exact Sciences to participate in Canaccord Genuity 36th Annual Growth Conference
-
Pre-Open Stock Movers 07/28: (GRPN) (N) (ALR) (FB) Higher; (INFN) (ARGS) (RCII) (F) Lower (more...)
-
Exact Sciences Announces Upsizing and Pricing of Public Offering of Common Stock
-
After-Hours Stock Movers 07/27: (PCMI) (GRPN) (CRUS) (FB) Higher; (INFN) (ARGS) (RCII) Lower (more...)
-
Exact Sciences (EXAS) Falls 4% on Plans to Sell 7M Common Shares
-
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
-
Pre-Open Stock Movers 06/16: (PTX) (QLGC) (EXAS) Higher; (TNXP) (CAVM) (EVHC) Lower (more...)
-
Highlights from Exact Sciences (EXAS) Analyst Lunch - Canaccord
-
Exact Sciences to Participate in November Investor Conferences
-
Notable Analyst Rating Changes 10/21: (COH) (WM) (EXAS) Upgraded; (TWTR) (MU) (IAG) Downgraded
-
Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines
-
Canaccord Genuity Cuts Price Target on Exact Sciences (EXAS) Following Growth Conference
-
Exact Sciences to Participate in August Conferences
-
Canaccord Genuity Raises Price Target on Exact Sciences (EXAS) Ahead of Analyst Day
-
Canaccord Genuity Sees 'Significant Short Squeeze' in Exact Sciences (EXAS) Given CMS Pricing
-
Exact Sciences Corp (EXAS) Prices 10M Offering at $12.75/Share
-
Exact Sciences (EXAS) to Offering $125M Shares
-
Exact Sciences (EXAS) Prices 5.5M Shares at $12.35/Sh
-
Canaccord Genuity maintains a 'Buy' on Exact Sciences (EXAS); Q2 Preview: Unique Opportunity Presented

